Meningeal lymphatic vessels regulate brain tumor drainage and immunity.
Hu X, Deng Q, Ma L, Li Q, Chen Y, Liao Y, Zhou F, Zhang C, Shao L, Feng J, He T, Ning W, Kong Y, Huo Y, He A, Liu B, Zhang J, Adams R, He Y, Tang F, Bian X, Luo J. · 2020
Read Meningeal lymphatic vessels regulate brain tumor drainage and immunity. by Hu X, Deng Q, Ma L, Li Q, Chen Y, Liao Y, Zhou F, Zhang C, Shao L, Feng J, He T, Ning W, Kong Y, Huo Y, He A, Liu B, Zhang J, Adams R, He Y, Tang F, Bian X, Luo J. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7054407.txt.
Introduction
Hu and co-authors study the lymphatic vessels of the meninges in brain tumours for Cell Research. Meningeal lymphatic vessels drain fluid and carry immune cells from the central nervous system to cervical lymph nodes. Their part in brain tumour drainage and immunity was unexplored. The team examined these vessels in mice bearing gliomas or metastatic melanomas inside the skull.
The dorsal vessels remodelled extensively as tumours grew. Gene activity in their lining cells shifted toward drainage, inflammation, and immune functions. Disrupting the dorsal vessels impaired fluid drainage from tumours and reduced both cancer cell spread and dendritic cell traffic to deep cervical lymph nodes. Boosting vessel growth had the opposite effect. Most strikingly, broken dorsal vessels cut the benefit of combined anti-PD-1 and CTLA-4 checkpoint therapy, while tumours overproducing VEGF-C, a vessel growth factor, responded better. Drainage routes, it seems, help immunotherapy reach brain tumours.
Catalog record
| CREATOR | Hu X, Deng Q, Ma L, Li Q, Chen Y, Liao Y, Zhou F, Zhang C, Shao L, Feng J, He T, Ning W, Kong Y, Huo Y, He A, Liu B, Zhang J, Adams R, He Y, Tang F, Bian X, Luo J. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 71 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Meningeal lymphatic vessels regulate brain tumor drainage and immunity By Xueting Hu, Qiuping Deng, Lu Ma, Qingqing Li, Yidong Chen, Yuhan Liao, Fan Zhou, Chen Zhang, Linlin Shao, Jun Feng, Tubao He, Weihai Ning Published in: Cell Research DOI: 10.1038/s41422-020-0287-8 ABSTRACT Recent studies have shown that meningeal lymphatic vessels (MLVs), which are located both dorsally and basally beneath the skull, provide a route for draining macromolecules and trafficking immune cells from the central nervous system (CNS) into cervical lymph nodes (CLNs), and thus represent a potential therapeutic target for treating neurodegenerative and neuroinflammatory diseases. However, the roles of MLVs in brain tumor drainage and immunity remain unexplored. Here we show that dorsal MLVs undergo extensive remodeling in mice with intracranial gliomas or metastatic melanomas. RNA-seq analysis of MLV endothelial cells revealed changes in the gene sets involved in lymphatic remodeling, fluid drainage, as well as inflammatory and immunological responses. Disruption of dorsal MLVs alone impaired intratumor fluid drainage and the dissemination of brain tumor cells to deep CLNs (dCLNs). Notably, the dendritic cell (DC) trafficking from intracranial tumor tissues to dCLNs decreased in mice with defective dorsal MLVs, and increased in mice with enhanced dorsal meningeal lymphangiogenesis. Strikingly, disruption of dorsal MLVs alone, without affecting basal MLVs or nasal LVs, significantly reduced the efficacy of combined anti-PD-1/CTLA-4 checkpoint therapy in striatal tumor models. Furthermore, mice bearing tumors overexpressing VEGF-C displayed a better response to anti-PD-1/CTLA-4 combination therapy, and this was abolished by CCL21/CCR7 blockade, suggesting that VEGF-C potentiates checkpoint therapy via the CCL21/CCR7 pathway. Together, the results of our study not only demonstrate the functional aspects of MLVs as classic lymphatic vasculature, but also highlight that they are essential in generating an efficient immune response against brain tumors. INTRODUCTION The concept of immune privilege in the central nervous system (CNS) has been substantially reconsidered in the past decade.1 This concept was proposed more than half a century ago based on the experimental findings that foreign tissue grafts including tumors in the brain parenchyma were not rejected by the immune system of the host.2,3 Indeed, the CNS has unique anatomical features such as the blood–brain barrier and a lack of classic lymphatic vessels (LVs) in the parenchyma. However, evidence has emerged that CNS-derived soluble molecules and lymphocytes circulate through the healthy brain, and extensive cross-talk between the brain and the peripheral immune system exists under pathological conditions such as autoimmunity and infection.4 To visualize this process, fluorescent tracer dye was injected into the gray matter from where it migrates out to the cervical lymph nodes (CLNs).5 Subsequently, using a polarized macroscopic system, convective fluid fluxes with rapid interchange between cerebrospinal fluid (CSF) and interstitial fluid in the parenchyma were reported and named the “glymphatic” system based on its functional similarity to the lymphatic system in peripheral tissue, and on the important role of glial aquaporin-4 channels in the convective fluid transport.6 In searching for the pathways of immune cell movement and CSF drainage throughout the meninges, a lymphatic network in the dura mater situated bilaterally along the superior sagittal sinus (SSS) and transverse sinus (TS) has been recently rediscovered in rodents7,8 and humans,9 and has been shown to possess some of the classic lymphatic functions. These studies indicate that the immune system functions in some sub-regions of the CNS similarly to in the periphery. The features of meningeal LVs (MLVs) have been characterized and their functions in brain physiology have been gradually demonstrated. Like conventional lymphatic endothelial cells (LECs), meningeal LECs (MLECs) express the markers of CD31, VEGFR3, Prox1, PDPN, LYVE-1, and CCL21; and they efficiently drain both soluble molecules and immune cells from the subarachnoid space into CLNs.7,8 By injection of macromolecules, T cells, and dendritic cells (DCs) into the CSF, MLVs were shown to be capable of carrying CSF components and immune cells from the CNS to the CLNs in a physiological manner.10–12 Pathologically, while ablation of MLVs reduced the inflammatory responses in an animal model of multiple sclerosis,10 dysfunction of MLVs was shown to be an aggravating factor in the pathology of Alzheimer’s disease and age-associated cognitive decline.11,13 Together, MLVs play an important role in connecting the CNS to peripheral immunity and thus represent a promising therapeutic target for neurodegenerative and neuroinflammatory diseases. In contrast to the above findings that were obtained with the MLVs located at the dorsal part of the skull,7,8 several recent studies support the role of the basal MLVs in drainage of fluid from the CNS.14–16 Consistently, a very recent study showed that the MLVs located at the basal part of the skull appeared to be morphologically distinct and have stronger draining functions than dorsal MLVs.11 Therefore, the structural and functional relationships and inter-dependence of these MLVs need to be further investigated. Brain tumors, including primary and metastatic tumors, are among the most feared of all forms of cancer with very limited treatment options and a poor prognosis.17–19 Malignant cerebral gliomas, the most common primary tumor in the CNS, comprising ~80% of all malignant primary brain tumors,20 have a strong tendency to infiltrate.21 Nevertheless, metastatic brain tumors are the most frequently occurring intracranial tumors.22 It is well known that, among common cancers, metastatic melanoma has the highest risk of spreading to the CNS; it has a marked propensity to metastasize to the brain where it is characterized by meningeal and ventricular metastases.18 For decades it has been known that brain tumors can elicit potent antitumor immune responses. Specifically, using animal models, it has been demonstrated that soluble tumor antigens within the CNS can reach the CLNs via CSF drainage to stimulate specific T cells.23 Function-blocking antibodies against PD-1 and CTLA-4 have been shown to enhance antitumor T cell responses and resulted in durable antitumor activity in several mouse intracranial tumor models and clinical trials in patients.24–27 However, the response of brain tumors to immunotherapy is relatively weak and survival is still poor, suggesting that more attention should be paid to understand the immunity in brain tumors. Tumor-associated lymphatics are critical for the drainage of intratumor fluid, macromolecules (antigens), metastasis, and immunity.28–31 The role of MLVs linking the CNS to peripheral immunity prompted us to study their involvement in the fluid drainage of brain tumors and immunity. One intriguing question is whether MLVs act as a route out of the tumor that can be used for fluid drainage and tumor dissemination. In addition, it is important to determine whether and how MLVs participate in tumor immune responses, although MLVs within the dura mater are not physically close to tumors in the parenchyma. To investigate the roles of MLVs in the fluid drainage of brain tumors and immunity, we developed two mouse models with GL261 or B16 cells injected beneath the dura or in the striatum. We found that intracranial tumors induced extensive remodeling of dorsal MLVs, while basal MLVs underwent only mild remodeling at the late stage of tumor progression. Consistently, we found that specific pharmacochemical ablation of dorsal MLVs significantly blocked DC trafficking from brain tumors to dCLNs, and reduced the efficacy of anti-PD-1/CTLA-4 combination therapy. Mechanistically, we demonstrated that VEGF-C mediated the potentiation of immunotherapy and this was dependent on CCL21/CCR7 signaling. Our findings demonstrate that the dorsal MLVs play an essential role